Floatz logo

APG 115

CMML

Ascentage Pharma Group Inc.Small moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the CMML cohort.

Asset / SponsorPhaseRating
Equine Atg
DKMS gemeinnützige GmbH
Phase 3B
ff-10501-01
Fujifilm Pharmaceuticals U.S.A., Inc.
Phase 1/2CCC
Ocifisertib
Treadwell Therapeutics, Inc
Phase 1/2CCC
io-202
Immune-Onc Therapeutics
Phase 1CC
Rgi-2001
Zachariah Michael DeFilipp
Phase 1CC
lp-108
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1CC
E-6201
Spirita Oncology, LLC
Phase 1/2D

Same molecule, other indications

APG 115 is also rated in:

non-Hodgkin lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
T-cell prolymphocytic leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →
High-risk Myelodysplastic SyndromeDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →